An in-vivo pilot study into the effects of FDG-mNP in cancer in mice

Omer Aras*, Gillian Pearce, Adam J. Watkins, Fuad Nurili, Emin Ilker Medine, Ozge Kozgus Guldu, Volkan Tekin, Julian Wong, Xianghong Ma, Richard Ting, Perihan Unak, Oguz Akin, Bing Xu

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review



Previously, fluorodeoxy glucose conjugated magnetite nanoparticles (FDG-mNPs) injected into cancer cells in conjunction with the application of magnetic hyperthermia have shown promise in new FDG-mNPs applications. The aim of this study was to determine potential toxic or unwanted effects involving both tumour cells and normal tissue in other organs when FDG-mNPs are administered intravenously or intratumourally in mice.

Materials and methods

FDG-mNPs were synthesized. A group of six prostate-tumour bearing mice were injected with 23.42 mg/ml FDG-mNPs (intravenous injection, n = 3; intratumoural injection into the prostate tumour, n = 3). Mice were euthanized and histological sampling of tissue was conducted for the prostate tumour, as well as for lungs, lymph nodes, liver, kidneys, spleen, and brain, at 1 hour (n = 2) and 7 days (n = 4) post-injection. A second group of two normal (non-cancerous) mice received the same injection intravenously into the tail vein and were euthanised at 3 and 6 months post-injection, respectively, to investigate if FDG-mNPs remained in organs at those time points.


In prostate-tumour bearing mice, FDG-mNPs concentrated in the prostate tumour, while relatively small amounts were found in the organs of other tissues, particularly the spleen and the liver; FDG-mNP concentrations decreased over time in all tissues. In normal mice, no detrimental effects were found in either mouse at 3 or 6 months.


Intravenous or intratumoural FDG-mNPs can be safely administered for effective cancer cell destruction. Further research on the clinical utility of FDG-mNPs will be conducted by applying hyperthermia in conjunction with FDG-mNPs in mice.
Original languageEnglish
Article numbere0202482
JournalPLoS ONE
Issue number8
Publication statusPublished - 20 Aug 2018

Bibliographical note

This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: This research was funded by Memorial Sloan Kettering Cancer Centre, Department of Radiology, and the NIH/NCI Cancer Center Support Grant P30 CA008748, NIH Small-Animal Imaging Research Program (SAIRP), R24 CA83084; NIH Prostate SPORE, P50-CA92629; Ege University, Institute of Nuclear Sciences, Department of Nuclear Applications, 35100 Turkey; School of Engineering and Applied Science, Aston University, Birmingham, UK, B4 7E and Mr Julian Wong FRCS, Division of Vascular & Endovascular Surgery Department of Cardiac, Thoracic & Vascular Surgery National University Heart Centre, Singapore 1E Kent Ridge Road NUHS Tower Block, Level 9, Singapore 119228.


Dive into the research topics of 'An in-vivo pilot study into the effects of FDG-mNP in cancer in mice'. Together they form a unique fingerprint.

Cite this